Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -31.32 Billion KRW | -637.4% |
| 2022 | -4.24 Billion KRW | -51.91% |
| 2021 | -2.79 Billion KRW | 72.32% |
| 2020 | -10.1 Billion KRW | -35.91% |
| 2019 | -7.43 Billion KRW | -105.1% |
| 2018 | 145.67 Billion KRW | 1213.45% |
| 2017 | 11.09 Billion KRW | -29.84% |
| 2016 | 15.8 Billion KRW | -37.12% |
| 2015 | 25.13 Billion KRW | 6.45% |
| 2014 | 23.61 Billion KRW | 20.91% |
| 2013 | 19.53 Billion KRW | 18.29% |
| 2012 | 16.51 Billion KRW | 157.75% |
| 2011 | 6.4 Billion KRW | -76.61% |
| 2010 | 27.39 Billion KRW | -1.72% |
| 2009 | 27.87 Billion KRW | -9.74% |
| 2008 | 30.88 Billion KRW | -5.91% |
| 2007 | 32.82 Billion KRW | 67.91% |
| 2006 | 19.54 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 99 Million KRW | 104.48% |
| 2024 Q1 | -2.55 Billion KRW | 76.31% |
| 2024 Q2 | -3.45 Billion KRW | -35.22% |
| 2023 Q1 | -5.67 Billion KRW | -448.49% |
| 2023 FY | -31.32 Billion KRW | -637.4% |
| 2023 Q2 | 483.01 Million KRW | 108.52% |
| 2023 Q3 | -16.11 Billion KRW | -3435.52% |
| 2023 Q4 | -10.79 Billion KRW | 32.98% |
| 2022 Q2 | -421.39 Million KRW | 80.13% |
| 2022 Q1 | -2.12 Billion KRW | -211.08% |
| 2022 FY | -4.24 Billion KRW | -51.91% |
| 2022 Q3 | -1.96 Billion KRW | -365.71% |
| 2022 Q4 | 1.62 Billion KRW | 182.91% |
| 2021 FY | -2.79 Billion KRW | 72.32% |
| 2021 Q1 | -3.21 Billion KRW | -106.92% |
| 2021 Q3 | 657.42 Million KRW | 346.68% |
| 2021 Q2 | -266.5 Million KRW | 91.71% |
| 2021 Q4 | 1.9 Billion KRW | 190.37% |
| 2020 Q1 | -944.42 Million KRW | -116.31% |
| 2020 Q3 | -6.15 Billion KRW | -523.83% |
| 2020 Q4 | -1.55 Billion KRW | 74.75% |
| 2020 Q2 | 1.45 Billion KRW | 253.82% |
| 2020 FY | -10.1 Billion KRW | -35.91% |
| 2019 Q3 | -3.48 Billion KRW | 71.98% |
| 2019 Q4 | 5.78 Billion KRW | 266.35% |
| 2019 Q1 | 2.7 Billion KRW | 163.45% |
| 2019 FY | -7.43 Billion KRW | -105.1% |
| 2019 Q2 | -12.42 Billion KRW | -559.99% |
| 2018 FY | 145.67 Billion KRW | 1213.45% |
| 2018 Q3 | 143.9 Billion KRW | 5596.89% |
| 2018 Q4 | -4.25 Billion KRW | -102.96% |
| 2018 Q2 | 2.52 Billion KRW | -27.76% |
| 2018 Q1 | 3.49 Billion KRW | 1221.2% |
| 2017 Q3 | 3.21 Billion KRW | 68.87% |
| 2017 Q1 | 5.7 Billion KRW | 308.89% |
| 2017 Q2 | 1.9 Billion KRW | -66.67% |
| 2017 FY | 11.09 Billion KRW | -29.84% |
| 2017 Q4 | 264.65 Million KRW | -91.76% |
| 2016 Q3 | -812.03 Million KRW | -118.05% |
| 2016 FY | 15.8 Billion KRW | -37.12% |
| 2016 Q2 | 4.49 Billion KRW | -69.71% |
| 2016 Q4 | -2.73 Billion KRW | -236.6% |
| 2016 Q1 | 14.85 Billion KRW | 252.31% |
| 2015 Q4 | 4.21 Billion KRW | -58.14% |
| 2015 Q2 | 4.75 Billion KRW | -22.16% |
| 2015 FY | 25.13 Billion KRW | 6.45% |
| 2015 Q3 | 10.07 Billion KRW | 112.01% |
| 2015 Q1 | 6.1 Billion KRW | 37.66% |
| 2014 Q4 | 4.43 Billion KRW | -31.28% |
| 2014 Q2 | 5.79 Billion KRW | -16.43% |
| 2014 Q1 | 6.93 Billion KRW | 82.62% |
| 2014 Q3 | 6.45 Billion KRW | 11.3% |
| 2014 FY | 23.61 Billion KRW | 20.91% |
| 2013 Q4 | 3.79 Billion KRW | -41.31% |
| 2013 FY | 19.53 Billion KRW | 18.29% |
| 2013 Q2 | 5.12 Billion KRW | 23.91% |
| 2013 Q1 | 4.13 Billion KRW | -33.82% |
| 2013 Q3 | 6.47 Billion KRW | 26.23% |
| 2012 Q2 | 3.19 Billion KRW | 1318.7% |
| 2012 Q3 | 6.83 Billion KRW | 113.65% |
| 2012 FY | 16.51 Billion KRW | 157.75% |
| 2012 Q1 | 225.52 Million KRW | 0.0% |
| 2012 Q4 | 6.25 Billion KRW | -8.56% |
| 2011 Q3 | 4.28 Billion KRW | -30.43% |
| 2011 Q2 | 6.15 Billion KRW | -45.65% |
| 2011 Q1 | 11.31 Billion KRW | 103.48% |
| 2011 FY | 6.4 Billion KRW | -76.61% |
| 2010 FY | 27.39 Billion KRW | -1.72% |
| 2010 Q3 | 6.18 Billion KRW | 42.75% |
| 2010 Q4 | 5.56 Billion KRW | -10.02% |
| 2010 Q2 | 4.33 Billion KRW | -34.79% |
| 2010 Q1 | 6.64 Billion KRW | -16.72% |
| 2009 Q4 | 7.97 Billion KRW | 17.29% |
| 2009 FY | 27.87 Billion KRW | -9.74% |
| 2009 Q1 | - KRW | -100.0% |
| 2009 Q2 | 6.46 Billion KRW | 0.0% |
| 2009 Q3 | 6.79 Billion KRW | 5.24% |
| 2008 FY | 30.88 Billion KRW | -5.91% |
| 2008 Q2 | 8 Billion KRW | 0.0% |
| 2008 Q3 | 7.57 Billion KRW | -5.47% |
| 2008 Q4 | 6.69 Billion KRW | -11.56% |
| 2008 Q1 | - KRW | -100.0% |
| 2007 Q2 | 6.67 Billion KRW | 0.0% |
| 2007 Q4 | 10.15 Billion KRW | 10.38% |
| 2007 FY | 32.82 Billion KRW | 67.91% |
| 2007 Q3 | 9.2 Billion KRW | 37.81% |
| 2006 FY | 19.54 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -336.292% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 154.026% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 47.422% |
| HANDOK Inc. | -28.79 Billion KRW | -8.793% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -272.299% |
| Yuhan Corporation | 93.5 Billion KRW | 133.504% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 381.679% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | -26.268% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 121.425% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 992.937% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -1149.979% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -1410.657% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -592.393% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 240.286% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -336.292% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | -49.61% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 974.306% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 73.51% |
| JW Holdings Corporation | 19.02 Billion KRW | 264.665% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 60.306% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 114.742% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 184.66% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 45.348% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 611.775% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 1983.313% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 725.999% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -336.292% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 184.754% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 128.098% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 184.66% |
| Yuhan Corporation | 93.5 Billion KRW | 133.504% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | -92.801% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -708.394% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 611.987% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 184.66% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 265.715% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 164.916% |
| CKD Bio Corp. | -24.19 Billion KRW | -29.501% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 230.994% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 214.182% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 205.224% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 45.348% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 166.648% |
| Boryung Corporation | 40.2 Billion KRW | 177.929% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -1149.979% |
| JW Lifescience Corporation | 28.14 Billion KRW | 211.319% |